Carcinogenesis, Teratogenesis & Mutagenesis ›› 2024, Vol. 36 ›› Issue (1): 80-83.doi: 10.3969/j.issn.1004-616x.2024.01.014
Received:2023-01-04
Revised:2023-06-12
Online:2024-02-19
Published:2024-02-19
CLC Number:
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
| [1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. [2] JANJIGIAN Y Y, SHITARA K, MOEHLER M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma(CheckMate 649):a randomised, open-label, phase 3 trial[J]. Lancet,2021, 398(10294):27-40. [3] KONO K, NAKAJIMA S, MIMURA K. Current status of immune checkpoint inhibitors for gastric cancer[J]. Gastric Cancer, 2020, 23(4):565-578. [4] AHMADZADEH M, JOHNSON L A, HEEMSKERK B, et al. Tumor antigen-specific CD8+T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired[J]. Blood, 2009, 114(8):1537-1544. [5] ZHANG Y Z, YANG Y, CHEN Y R, et al. PD-L1:biological mechanism, function, and immunotherapy in gastric cancer[J]. Front Immunol, 2022, 13:1060497. [6] LIU X T, HOGG G D, DENARDO D G. Rethinking immune checkpoint blockade:‘Beyond the T cell’[J]. J Immunother Cancer, 2021, 9(1):e001460. [7] ZHANG A Z, YUAN X, LIANG W H, et al. Immune infiltration in gastric cancer microenvironment and its clinical significance[J]. Front Cell Dev Biol, 2021, 9:762029. [8] HAN J Q, ZHAO L L, WU J Y, et al. Role of CD4+T, CD8+T cells, and CD4+T/CD8+T cell ratio in gastric cancer and its clinical significance[J].Appl Bionics Biomech, 2022, 2022:1094607. [9] LIU Y T, SUN Z J. Turning cold tumors into hot tumors by improving T-cell infiltration[J]. Theranostics, 2021, 11(11):5365-5386. [10] FARHOOD B, NAJAFI M, MORTEZAEE K. CD8+cytotoxic T lymphocytes in cancer immunotherapy:a review[J]. J Cell Physiol, 2019, 234(6):8509-8521. [11] BALANÇA C C, SALVIONI A, SCARLATA C M, et al. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+CD4 T cells[J]. JCI Insight, 2021, 6(2):e142513. [12] LI X, ZHAI J, SHEN Y K, et al. Tumor-derived IL-8 facilitates lymph node metastasis of gastric cancer via PD-1 up-regulation in CD8+T cells[J]. Cancer Immunol Immunother, 2022, 71(12):3057-3070. [13] WANG F H, ZHANG X T, LI Y F, et al. The Chinese Society of Clinical Oncology(CSCO):clinical guidelines for the diagnosis and treatment of gastric cancer, 2021[J]. Cancer Commun, 2021, 41(8):747-795. [14] PEREIRA M A, DE CASTRIA T B, RAMOS M F K P, et al. Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer:prognosis and association with PD-L1 expression[J]. J Surg Oncol, 2021, 124(7):1040-1050. [15] SHEN Y, TENG Y S, LV Y P, et al. PD-1 does not mark tumor-infiltrating CD8+T cell dysfunction in human gastric cancer[J]. J Immunother Cancer, 2020, 8(2):e000422. [16] LIN F Y, CHEN H, JIANG T, et al. The effect of low-dose chemotherapy on the tumor microenvironment and its antitumor activity combined with anti-PD-1 antibody[J]. Immunotherapy, 2022:35259922. [17] CHEN Y, JIA K R, SUN Y, et al. Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment[J]. Nat Commun, 2022, 13(1):4851. [18] CHALABI M, VERSCHOOR Y L, VAN DE HAAR J, et al. 1219P Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction(G/GEJ)adenocarcinoma:the PANDA study[J]. Ann Oncol, 2022, 33:S1106. [19] KHAN M, AROOJ S, WANG H. NK cell-based immune checkpoint inhibition[J]. Front Immunol, 2020, 11:167. [20] HSU J, HODGINS J J, MARATHE M, et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade[J]. J Clin Invest,2018, 128(10):4654-4668. [21] GUO S W, HUANG C, HAN F F, et al. Gastric cancer mesenchymal stem cells inhibit NK cell function through mTOR signalling to promote tumour growth[J]. Stem Cells Int, 2021, 2021:9989790. [22] KYRYSYUK O, WUCHERPFENNIG K W. Designing cancer immunotherapies that engage T cells and NK cells[J]. Annu Rev Immunol, 2023, 41:17-38. [23] YAMASHITA K, IWATSUKI M, YASUDA-YOSHIHARA N, et al.Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer[J]. Br J Cancer,2021, 124(3):595-603. [24] DUHEN T, DUHEN R, LANZAVECCHIA A, et al. Functionally distinct subsets of human FOXP3+Treg cells that phenotypically mirror effector Th cells[J]. Blood, 2012, 119(19):4430-4440. [25] SHI L S, FENG M, DU S C, et al. Adenosine generated by regulatory T cells induces CD8+T cell exhaustion in gastric cancer through A2aR pathway[J]. Biomed Res Int, 2019, 2019:4093214. [26] TADA Y, TOGASHI Y, KOTANI D, et al. Targeting VEGFR2 with Ramucirumab strongly impacts effector/activated regulatory T cells and CD8+T cells in the tumor microenvironment[J]. J Immunother Cancer,2018, 6(1):106. [27] KWON M, AN M, KLEMPNER S J, et al. Determinants of response and intrinsic resistance to PD-1 blockade in microsatellite instability-high gastric cancer[J]. Cancer Discov, 2021, 11(9):2168-2185. [28] WANG Q Y, XIE B, LIU S, et al. What happens to the immune microenvironment after PD-1 inhibitor therapy?[J]. Front Immunol,2021, 12:773168. [29] KAMADA T, TOGASHI Y, TAY C, et al. PD-1+regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer[J].Proc Natl Acad Sci USA, 2019, 116(20):9999-10008. [30] GREENBERG P D, KERN D E, CHEEVER M A. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+, 2-T cells. Tumor eradication does not require participation of cytotoxic T cells[J]. J Exp Med, 1985, 161(5):1122-1134. [31] ESCORS D, BOCANEGRA A, CHOCARRO L, et al. Systemic CD4immunity and PD-L1/PD-1 blockade immunotherapy[J]. Int J Mol Sci,2022, 23(21):13241. [32] HELMINK B A, REDDY S M, GAO J J, et al. B cells and tertiary lymphoid structures promote immunotherapy response[J]. Nature, 2020,577(7791):549-555. [33] GOU M M, QU T T, WANG Z K, et al. Neutrophil-to-lymphocyte ratio(NLR)predicts PD-1 inhibitor survival in patients with metastatic gastric cancer[J]. J Immunol Res, 2021, 2021:2549295. [34] YUAN J J, ZHAO X W, LI Y Y, et al. The association between blood indexes and immune cell concentrations in the primary tumor microenvironment predicting survival of immunotherapy in gastric cancer[J]. Cancers, 2022, 14(15):3608. [35] KIM K H, CHO J, KU B M, et al. The first-week proliferative response of peripheral blood PD-1+CD8+T cells predicts the response to antiPD-1 therapy in solid tumors[J]. Clin Cancer Res, 2019, 25(7):2144-2154. [36] ABDOLAHI S, GHAZVINIAN Z, MUHAMMADNEJAD S, et al.Adaptive NK cell therapy modulated by anti-PD-1 antibody in gastric cancer model[J]. Front Pharmacol, 2021, 12:733075. [37] NOSE Y, SAITO T, YAMAMOTO K, et al. The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1therapy in gastric cancer[J]. Cancer Immunol Immunother, 2023, 72(1):169-181. [38] SHEN R L, POSTOW M A, ADAMOW M, et al. LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade[J]. Sci Transl Med, 2021, 13(608):eabf5107. [39] OHMURA H, YAMAGUCHI K, HANAMURA F, et al. OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody[J]. Br J Cancer, 2020, 122(10):1507-1517. [40] LOZANO A X, CHAUDHURI A A, NENE A, et al. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma[J]. Nat Med, 2022, 28(2):353-362. [41] ZHU C Q, SHI Y Y, LI Q P, et al. Rational administration sequencing of immunochemotherapy elicits powerful anti-tumor effect[J]. J Control Release, 2022, 341:769-781. [42] WANG Y Y, ZHU C C, SONG W, et al. PD-L1 expression and CD8+T cell infiltration predict a favorable prognosis in advanced gastric cancer[J]. J Immunol Res, 2018, 2018:4180517. [43] THOMPSON E D, ZAHURAK M, MURPHY A, et al. Patterns of PD-L1 expression and CD8+T cell infiltration in gastric adenocarcinomas and associated immune stroma[J]. Gut, 2017, 66(5):794-801. [44] WANG J T, LI R C, CAO Y F, et al. Intratumoral CXCR5+CD8+T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer[J]. Nat Commun, 2021, 12(1):3080. |
| [1] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 70-76. |
| [2] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(6): 481-484. |
| [3] | ZHAO Yan, SUN Zhenxiao. Metformin inhibitd proliferation and migration of human breast cancer cell in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 35-39. |
| [4] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 72-74. |
| [5] | ZHANG Zongming. Does thyroid microcarcinoma require surgery [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 325-326. |
| [6] | CHENG Shujun. Aging and malignant tumor─Thought on prevention and control [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 161-162. |
| [7] | ZHANG Die, LIU Xianghe, HUO Miaomiao, LIU Mei, XU Ningzhi, ZHU Hongxia. Effects of miR-195-5p on radiosensitivity of esophageal squamous cell carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 81-88,94. |
| [8] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 398-401. |
| [9] | ZHANG Fan, LIU Guangchao, ZHANG Zhihan, LIU Fangfang, XIE Qi, GAO Shuqing. Effect of ketogenic diet on growth of subcutaneously transplanted human lung cancer in nude mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 286-291. |
| [10] | WANG Ziyi, ZHANG Lulu, SUN Zhenxiao, LIU Changzhen. Fludarabine combined with TRAIL induced apoptosis in lung cancer A549 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 203-207. |
| [11] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 249-252,256. |
| [12] | ZHANG Ju, YE Shulai, ZHANG Changlong, ZHOU Qian. Stimulation of dendritic cell-mediated antitumor tumor effect from HepG2 cell exosomes [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(1): 29-34. |
| [13] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(2): 161-163. |
| [14] | . [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(2): 158-160. |
| [15] | GUO Xiao, WANG Rui, WU Juan, JI Xiaokun, WANG Heng, ZHANG Yan, MA Yang, DU Yun. Significance of EGFR gene mutation in fresh cytological specimens of lung adenocarcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(1): 67-70. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
